| LONDON, December 14, 2011 /PRNewswire/ -- http://www.visiongain.com/Report/735/Mobile-Messaging-Market-Report-2011-2016 Visiongain's latest research entitled "Mobile Messaging Market Report: 2011 - 2016" offers a fine-tuned analysis of four mobile messaging platforms: SMS, MMS, instant messaging and email. The mobile messaging market is under strong pressure to evolve and adapt alongside technical innovation and changes in consumer demands. The strong growth of mobile broadband is the result of increased mobile data usage by subscribers hungry for instant communication, multimedia sharing and social networking. Instant messaging and email applications are fast becoming default services in smart devices. Smartphones and mobile broadband are not the only vectors for the transformation of the mobile messaging market. SMS and MMS have also evolved beyond their traditional platforms to more enhanced and personalised applications. Ubiquitous wireless connectivity and basic feature phones have become quasi-universal on a global scale. In many regions, basic mobile messaging is serving as an efficient and reliable platform for value added services in mobile banking, commerce and health. The mobile messaging market is undergoing a structural shift and opening up to new players offering high-value functionalities. Visiongain estimates the current market to be valued at US $202 billion which represents on average 19% of total global mobile revenues. While North America and Europe will show a strong uptake and diversification in instant messaging and email services, emerging economies in Africa, the Middle East and Asia will see continued growth and expansion of traditional SMS and MMS platforms and their use in new industries. Visiongain's report presents a detailed breakdown of the four mobile messaging ecosystems, including market dynamics, the role of different industry stakeholders and the financial forecasts for revenue and subscriptions evolution at the global and regional level. The research analyses the emerging trends and opportunities for operators, content and service providers, manufacturers, commercial organisations as well as government institutions to harness the potential offered by messaging platforms in an increasingly mobile world. To view sample pages please click on: http://www.visiongain.com/Report/735/Mobile-Messaging-Market-Report-2011-2016 1. Executive Summary 1.1 Summary Points of this Report 1.2 Aims, Scope and Format of the Report 1.2.1 Speculative Aspects of Assessing the Biobanking Market 1.2.2 Chapter Outlines 1.3 Research and Analysis Methods 1.3.1 Human Tissue Banking Market 1.3.2 Stem Cell Banking Market 2. Introduction to Biobanking 2.1 Biobanking 2.1.1 Processes Involved in Biobanking 2.2 Biobanks: A Two-Fold Character 2.3 Key Features 2.4 Classification of Biobanks 2.4.1 Volunteer Groups 2.4.1.1 Population-Based Biobanks 2.4.1.2 Disease-Oriented Biobanks 2.4.2 Ownership or Funding Structure 2.5 Guidelines and Standards 2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research 2.5.2 Industry Standards for Biobanks 2.5.3 Biobanking Processes Governed by Guidelines 2.6 Laws and Regulations for Biobank-Based Research 3. Biobanking and the Pharmaceutical Industry 3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry 3.1.1 Research and Drug Development 3.1.1.1 Understanding Disease Pathways 3.1.1.2 Drug Discovery 3.1.1.3 Biomarker Discovery 3.1.2 Therapeutics 3.1.3 Clinical Trials 3.2 Biobanks Operated by Pharmaceutical Companies 4. Biobanking Associated Market: Systems, Software, Consumables and Services Associated with Biobanking 4.1 Overview 4.2 Systems/Technologies 4.2.1 Automated Liquid Handling 4.2.1.1 Frozen Aliquotting: New Technology in Development 4.2.2 Storage 4.2.2.1 Ultra-Low Temperature Freezing 4.2.2.2 Room-Temperature Storage 4.2.3 RFID and Tagging Technologies 4.3 Software 4.3.1 Laboratory Information Management System (LIMS) 4.3.1.1 LIMS Functions 4.4 Consumables 4.5 Services 5. The World Medical Biobanking Market to 2022 5.1 Current State of the Biobanking Market 5.2 Geographical Footprint 5.3 Growing Demand for Biobank Resources 5.4 Revenue Forecast for Overall Market 5.4.1 Scope and Limitations 5.4.2 Biobanking Market, 2011-2022 5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016 5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022 5.5 Commercial Biobanks: New Resources for Research 6. Human Tissue Banking Market 6.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2022 6.1.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2016 6.1.2 Revenue Forecast for Overall Human Tissue Banking Market, 2017-2022 6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2011-2022 6.2.1 Revenue Forecast for Commercial Human Tissue Banking Market, 2011-2016 6.2.2 Revenue Forecast for Commercial Human Tissue Banking Market, 2017-2022 6.2.3 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2011-2016 6.2.4 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2017-2022 6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2011-2022 6.4 Some Commercial Participants in the Human Tissue Banking Market 6.4.1 Business Models of Companies in the Biobanking Market 6.4.2 Tissue Solutions 6.4.2.1 Overview 6.4.2.2 Global Presence 6.4.2.3 Products and Services 6.4.2.3.1 Banked Samples 6.4.2.3.2 Prospective Samples 6.4.2.3.3 Fresh Samples 6.4.2.3.4 Freshly Isolated and Primary Cells 6.4.2.3.5 Services 6.4.2.4 Strengths and Capabilities 6.4.2.5 Future Outlook 6.4.3 Asterand 6.4.3.1 Overview 6.4.3.2 Global Presence 6.4.3.3 Products and Services 6.4.3.3.1 XpressBANK 6.4.3.3.2 ProCURE 6.4.3.3.3 PhaseZERO 6.4.3.3.4 BioMAP 6.4.3.4 Asterand: Raised Barriers for New Market Entrants? 6.4.3.5 Financial Performance 6.4.3.6 Future Outlook 7. Stem Cell Banking 7.1 Overview 7.2 Revenue Forecast for Overall Stem Cell Banking Market, 2011-2022 7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016 7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022 7.3 Stem Cell Banks for Research: High Growth Possible 7.4 Umbilical Cord Blood Banking for Stem Cells 7.4.1 Blood Banks: Private vs. Public 7.4.2 Biological Insurance: Private Blood Banking 7.4.3 Umbilical Cord Banking: The Controversies 7.4.3.1 US Oversight of Cord Blood Stem Cells 7.4.4 Revenue Forecast for Private Cord Blood Banking Market, 2011-2016 7.4.5 Revenue Forecast for Private Cord Blood Banking Market, 2017-2022 7.4.6 Companies in the Field 7.4.6.1 Cord Blood America: Looking Towards the Chinese Market 7.4.6.2 ViaCord: 145,000 Blood Units in Storage 7.4.6.3 Cryo-Cell International: The First Cord Blood Bank 7.4.6.4 Stem Cell Authority: Exclusive Stem Cells 7.4.6.5 LifebankUSA: Placenta-Cord Banking 7.4.6.6 Biogenea-Cellgenea 7.4.6.7 China Cord Blood Corp 7.4.6.8 Cryo-Save 7.4.6.9 Thermogenesis 7.5 Gene/DNA Banking 8. Industry Trends 8.1 Automated Biobanking 8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking 8.1.2 Addressing Sample Storage and Tracking Issues 8.2 Green Banking 8.3 Creation of National Biobanks 8.4 HIPAA Amendments 9. Qualitative Analysis of the Biobanking Sector 9.1 Strengths 9.1.1 Wealth of Information for Genetic Research 9.1.2 Potential to Change Treatments 9.1.3 Many Governments Support Biobanking 9.2 Weaknesses 9.2.1 Quality Concerns for Some Existing Biospecimen Collections 9.2.2 Lack of Standardisation and Harmonisation of Best Practices 9.2.3 Limited Sharing and Linkage of Biobanks 9.3 Opportunities 9.3.1 Genome-Wide Association Studies (GWAS) 9.3.2 Personalised Medicine 9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach 9.4 Threats 9.4.1 Ethical and Regulatory Issues 9.4.1.1 Limitations of Informed Consent in Biobanking 9.4.1.2 Confidentiality and Security to Prevent Improper Use 9.4.2 Social and Cultural Issues 9.4.3 Ownership Issues 9.4.4 Funding 10. Research Interviews from Our Survey 10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions 10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry 10.1.2 On Commercial Aspects of Biobanking 10.1.3 On the Business of Tissue Solutions 10.1.4 On the Attractiveness of Human Tissue Banking 10.1.5 On the Future of the Biobanking Market 10.2 Dr Angel GarcÃa MartÃn, Director, Inbiomed 10.2.1 On the Importance of Biobanking in the Pharmaceutical Industry 10.2.2 On the Use of Technology in Biobanking 10.2.3 On Increased Recognition of Biobanking and Harmonisation of Samples 10.2.4 On the Use of Biobanks by the Pharmaceutical Industry 10.2.5 On Private Biobanks and Scale of Operations 10.2.6 On Commercial and Public Biobanking and Legislation 10.2.7 On the Most Attractive Segment in Commercial Biobanking 10.2.8 On the Future of Biobanking: Drivers and Challenges 10.3 Dr Piet Smet, Director, Business Development, BioStorage Technologies 10.3.1 On Defining Biorepositories and Biobanks 10.3.2 On the Services of Biostorage 10.3.3 On Main Customers for Biostorage 10.3.4 On the Importance of Biorepositories in Research and Industry 10.3.5 On Technology Use in Biobanks 10.3.6 On Increased Recognition of Biobanking and Harmonisation of Samples 10.3.7 On the Use of Biobanks by the Pharmaceutical Industry 10.3.8 On Private Biobanks and Scale of Operations 10.3.9 On Commercial and Public Biobanking and Legislation 10.3.10 On the Most Attractive Segment in Commercial Biobanking 10.3.11 On Biobanking in 2020 10.3.12 On Drivers and Challenges in the Sector 10.4 Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems 10.4.1 On the Services of SampleNavigator 10.4.2 On Main Customers for SampleNavigator 10.4.3 On the Importance of Biorepositories in Research and Industry 10.4.4 On Technology Use in Biobanks 10.4.5 On Increased Recognition of Biobanking and Harmonisation of Samples 10.4.6 On the Use of Biobanks by the Pharmaceutical Industry 10.4.7 On Commercial Biorepositories/Banks and Scale of Operations 10.4.8 On Commercial and Public Biobanking 10.4.9 On the Most Attractive Segment in Commercial Biobanking 10.4.10 On Biobanking in 2020 10.4.11 On Drivers and Challenges in the Sector 10.5 Mr Rob Fannon, Clinical Operations Manager, BioServe 10.5.1 On the Services of BioServe 10.5.2 On Main Customers for BioServe 10.5.3 On the Importance of Biorepositories in Research and Industry 10.5.4 On Technology Use in Biobanks 10.5.5 On Increased Recognition of Biobanking and Harmonisation of Samples 10.5.6 On the Use of Biobanks by the Pharmaceutical Industry 10.5.7 On Commercial Biorepositories/Banks and Scale of Operations 10.5.8 On Commercial and Public Biobanking 10.5.9 On the Most Attractive Segment in Commercial Biobanking 10.5.10 On Biobanking in 2020 10.5.11 On Drivers and Challenges in the Sector 10.6 Dr Frans A.L. van der Horst, Chairman, Dutch Collaborative Biobank 10.6.1 On Importance of Biorepositories in Research and Industry 10.6.2 On Increased Recognition of Biobanking and Harmonisation of Samples 10.6.3 On the Services of Dutch Collaborative Biobank 10.6.4 On Commercial Drivers for Bio-Repositories/Biobanking Market 10.6.5 On Commercial and Public Biobanking 10.6.6 On Sustaining/Recovering Costs 10.6.7 On the Most Attractive Segment in Commercial Biobanking 10.6.8 On Ethical, Legal and Social Issues in Biorepositories/Biobanks 11. Conclusions 11.1 Biobanking for Research and Therapeutics 11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine 11.3 Commercial Drivers of the Biobanking Market 11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth Companies Listed Abcellute Abgene Adnexus Therapeutics AFNOR Groupe AKH Biobank AlloSource American National Bioethics Advisory Commission American Type Culture Collection Amgen Analytical Biological Services ARCH Venture Partners Asterand AstraZeneca Australasian Biospecimen Network (ABN) Autoscribe AXM Pharma Bayer-Schering Beckman Coulter Beike Biotechnology Biobank Ireland Trust Biobank Japan Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) BioFortis Biogen Idec Biogenea-CellGenea BioLife Solutions Biomatrica Biopta BioRep BioSeek BioServe BioStorage LLC BioStorage Technologies BrainNet Europe Caliper LifeSciences Canadian Partnership for Tomorrow CARTaGENE Cellgene Corporation Cells4Health Chemagen China Cord Blood Corp Chinese Ministry of Health CLB/Amsterdam Medical Center CorCell Cord Blood America Cord Blood Registry CORD:USE (US Public Cord Blood Bank) CordLife Cordon Vital (CBR) Coriell Institute for Medical Research Council of Europe (CoE) Covance Cryo Bio System Cryo-Cell International Cryometrix Cryo-Save Cureline Cybrdi Danubian Biobank Foundation deCODE Genetics Department of Health (DoH, UK) Draper Laboratory Duke University Medical Center Dutch Collaborative Biobank EGeen Eli Lilly Eolas Biosciences Estonian Genome Project EuroBioBank European Commission (EC) European Health Risk Monitoring (EHRM) European Medicines Agency (EMA/EMEA) European Union Group on Ethics (EGE) Fisher BioServices Fondazione I.R.C.C.S. Istituto Neurologico C. Besta Food and Drug Administration (US FDA) Foundation for the National Institutes of Health Fundación Istituto Valenciano de OncologÃa Fundeni Clinical Institute Genentech Generation Scotland GeneSaver GeneSys Genetic Association Information Network (GAIN) Genizon Biosciences Genome Quebec Biobank GenomEUtwin Genomic Studies of Latvian Population GenVault German Dementia Competence Network GlaxoSmithKline (GSK) H. Lee Moffitt Cancer Center and Research Institute Hamilton Hopital Necker Paris - Necker DNA Bank Human Tissue Authority (HTA) Hungarian Biobank HUNT, Norway ILSBio LLC Inbiobank Inbiomed Indivumed INMEGEN Institut National de la Santé et de la Recherche Médicale (INSERM) Integrated BioBank of Luxembourg International Agency for Research on Cancer (IARC) International Air Transport Association (IATA) International Organization for Standardization (ISO) International Society for Biological and Environmental Repositories (ISBER) International Stem Cell Corporation Kaiser Permanente KORA-gen LabVantage Solutions LabWare Leiden University Medical Center LifebankUSA LifeGene LifeStem Malaysian Cohort Project Matrical Biosciences Matrix Medical Research Council (MRC) Medical University of Gdansk Merck & Co. Merck Sharp & Dohme Limited (MSD) Merck-Serono Micronic Millennium (Takeda Oncology Company) MVE-Chart National Cancer Institute (NCI) National DNA Bank (US) National Human Genome Research Institute (NHGRI) National Institute of Environmental Health National Institutes of Health (NIH) National Public Health Institute National Research Ethics Service (NRES) NeoCodex NeoStem Neuromuscular Bank of Tissues and DNA Samples New Brunswick Scientific NEXUS Biosystems Northwest Regional Development Agency Novacare Bio-Logistics Novartis NUgene Project Ocimum Biosolutions Office of Biorepositories and Biospecimen Research (OBBR) OnCore UK Organisation for Economic Co-operation and Development (OECD) OriGene Oxagen Pacific Bio-Material Management PathServe Perkin Elmer Pfizer Pharmagene Laboratories Trustees Limited Polaris Ventures Pop-Gen (University Hospital Schleswig-Holstein) PrecisionMed Prevention Genetics ProMedDx Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE) ProteoGenex Public Population Projects in Genomics (P3G Consortium) Qiagen RAND Corporation Regenetech REMP Reproductive Genetics Institute (RGI) Research Centre of Vascular Diseases, University of Milan Rhode Island BioBank, Brown University Roche RTS Life Science Saga Investments LLC SampleNavigator Laboratory Automation Systems Sanofi SANYO Biomedical Scottish Government Seattle Genetics Sejtbank (Hungarian Cord Blood Bank) SeqWright DNA Technology Services SeraCare Life Sciences Singapore Tissue Network StarLIMS Steelgate Stem Cell Authority Stem Cells for Safer Medicine (SC4SM) Stem Cells Research Forum of India Stemride International Taiwan Biobank Taizhou Biobank TAP Tecan The Automation Partnership The Sorenson Molecular Genealogy Foundation (SMGF) Thermo Fisher Scientific Thermogenesis Tissue Bank Cryo Center (Bulgaria) Tissue Solutions Titan Pharmaceuticals TotipotentSC Trinity Biobank Tumorothèque Necker-Entants Malades UK Biobank UK Stem Cell Bank UmanGenomics UmeÃ¥ University University Hospital Angers University Medical Center Gent University of Massachusetts Stem Cell Bank University of Tuebingen, Department of Medical Genetics US Biomax Västerbotten County Council ViaCord Wellcome Trust Wellcome Trust Case-Control Consortium (WTCCC) Western Australian Genome Health Project Wheaton Science International Wisconsin International Stem Cell (WISC) Bank World Health Organization (WHO) Zhejiang Lukou Biotechnology Co Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100 About visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. Please contact Sara Peerun for an exec summary: Email: sara.peerun@visiongainglobal.com Tel: +44-020-7336-6100 | |